Protagonist Therapeutics filings document formal disclosures for a biopharmaceutical company built around peptide therapeutics. Form 8-K reports furnish quarterly and annual financial results, corporate updates, Regulation FD presentations and material event exhibits tied to pipeline, collaboration and operating developments.
Proxy and annual meeting filings describe board elections, executive compensation votes, auditor ratification, equity incentive plan matters, stockholder voting results and the company's common stock voting structure. These records also frame governance, compensation and capital-related disclosures for Protagonist's Nasdaq-listed Delaware corporation.
Farallon Capital and affiliated funds report a significant stake in Protagonist Therapeutics, Inc. (PTGX). As of the triggering date, the Farallon funds together hold 6,221,006 common shares and 1,500,000 common stock purchase warrants.
The warrants are subject to a 9.99% beneficial ownership limitation, so only 27,007 warrant shares are currently counted toward ownership, with the remaining 1,472,993 treated as not exercisable within 60 days. Various Farallon entities and individuals each report up to 9.99% beneficial ownership, and the group files on a passive Schedule 13G basis. The amendment also adds Avner A. Husen as a reporting person and removes Richard B. Fried, Rajiv A. Patel, and William Seybold.
PTGX shareholder plans to sell 20,000 shares of common stock under Rule 144 through Morgan Stanley Smith Barney on or about 02/06/2026, with the shares listed on NASDAQ.
The planned sale has an aggregate market value of $1,673,672.00. Shares outstanding were 62,515,666; this is a baseline figure, not the amount being sold. The seller acquired the 20,000 shares the same day by exercising a stock option and paid the purchase price in cash.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 5,413,690 shares of Protagonist Therapeutics Inc common stock, representing 8.65% of the class as of 12/31/2025.
Vanguard reports shared voting power over 473,004 shares and shared dispositive power over 5,413,690 shares, with no sole voting or dispositive power. The securities are held in the ordinary course of business, and Vanguard states they were not acquired to change or influence control of Protagonist. Vanguard also notes an internal realignment effective January 12, 2026, after which certain subsidiaries may report beneficial ownership separately.
Protagonist Therapeutics President and CEO Dinesh V. Patel reported multiple stock transactions in January 2026. On January 23, 2026, he made a charitable donation of 6,000 shares of common stock to a donor-advised fund for charitable purposes.
Across January 23–27, 2026, he exercised vested stock options to acquire common shares at exercise prices of $4.21 and $21.58 per share and sold matching share amounts in open-market transactions at reported weighted average sale prices of $84.59, $84, $84.05 and $83.19 per share.
Following these transactions, he directly owned 574,505 shares of common stock and held 300,000 stock options with exercise price $21.58 expiring on October 11, 2026 and 10,685 stock options with exercise price $4.21 expiring on April 29, 2026.
Protagonist Therapeutics Chief Financial Officer Asif Ali reported multiple stock transactions on January 27, 2026. He exercised stock options for 16,000 common shares at $19.19 and 12,000 shares at $12.17, then sold 28,000 shares at a weighted average price of $83.13 and 18,203 shares at $83.14. After these transactions, he directly owned 60,320 common shares. The exercised options relate to grants from April 18, 2022 and January 16, 2023, which vest over time subject to his continued service.
Protagonist Therapeutics Chief Medical Officer Arturo Molina reported multiple stock option exercises and share sales. On January 26 and 27, 2026, he exercised a total of 10,000 stock options at an exercise price of $8.04 per share and acquired the same number of common shares.
He then sold 5,000 shares on each of January 26 and 27 at weighted average prices of $82.28 and $82 per share, and earlier sold 13,151 shares on January 23, 2026 at a weighted average price of $82.42 per share. After these transactions he directly owned 84,115 common shares and 65,971 stock options, with the option grant originally covering 127,500 shares and vesting through November 7, 2026.
Asif Ali has filed a notice of proposed sale of 46,203 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $3,841,128.28, to be sold on the NASDAQ on or about January 27, 2026.
The filing notes that 62,515,666 shares of the same class were outstanding, providing context for the size of the planned sale. In the prior three months, Asif Ali sold 8,588 common shares for gross proceeds of $708,327.08. The form includes a representation that the seller is not aware of undisclosed material adverse information about the issuer’s operations.
Arturo Molina has filed a Rule 144 notice to sell 5,000 shares of PTGX common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $410,000. These shares were acquired on 01/27/2026 via a stock option exercise paid in cash for 5,000 shares. The notice lists 62,515,666 common shares outstanding and anticipates sale on 01/27/2026 on the NASDAQ market.
Over the prior three months, the same seller reported additional PTGX common stock sales, including 9,514 shares on 01/20/2026 for $784,702.35 and 13,151 shares on 01/23/2026 for $1,097,115.60. The notice also records sales of 5,000 shares on 01/26/2026 for $411,396.00 and 2,712 shares on 11/18/2025 for $229,896.24. By signing, the seller represents not knowing any undisclosed material adverse information about PTGX.
Arturo Molina filed a Rule 144 notice to sell 5,000 shares of common stock of the PTGX issuer through Morgan Stanley Smith Barney LLC, with an aggregate market value of $411,396.00. The shares were acquired on 01/26/2026 via a stock option exercise from the issuer and paid for in cash the same day.
The notice also lists recent activity over the prior three months, including sales of 2,712 shares on 11/18/2025 for gross proceeds of $229,896.24, 13,151 shares on 01/23/2026 for $1,097,115.60, and 9,514 shares on 01/20/2026 for $784,702.35. The issuer reports 62,515,666 shares of this class outstanding, and the planned sale is to be executed on or about 01/26/2026 on the NASDAQ exchange.
Arturo Molina has filed a notice of proposed sale under Rule 144 to sell 13,151 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $1,097,115.60 and an approximate sale date of 01/23/2026. The table shows 62,515,666 common shares outstanding as a baseline figure.
The shares to be sold were acquired as restricted stock from the issuer in several grants on 11/15/2025 and 01/15/2026. Over the past three months, Molina has already sold 2,712 common shares on 11/18/2025 for gross proceeds of $229,896.24 and 9,514 common shares on 01/20/2026 for gross proceeds of $784,702.35. By signing, the seller represents not knowing any undisclosed material adverse information about the issuer's operations.